Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blinded, Adaptive Phase 2 Study to Evaluate the Safety and Efficacy of Oral Omadacycline and Oral Nitrofurantoin in the Treatment of Female Adults With Cystitis

NCT03425396 is registered in ClinicalTrials.gov with Paratek Pharmaceuticals Inc as lead sponsor.

NCT NCT03425396
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03425396 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blinded, Adaptive Phase 2 Study to Evaluate the Safety and Efficacy of Oral Omadacycline and Oral Nitrofurantoin in the Treatment of Female Adults With Cystitis
Lead sponsor
Paratek Pharmaceuticals Inc
Phase
Phase 2
Overall status
Completed
Start date
January 4, 2018
Completion date
June 5, 2019
Enrollment
225 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

cystitis, uncomplicated urinary tract infection